Drug development in cardiovascular disease is stagnating, with lack of efficacy and adverse
effects being barriers to innovation. Human genetics can provide compelling evidence of …

Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission
(CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends …

Mendelian randomisation (MR) studies allow a better understanding of the causal effects of
modifiable exposures on health outcomes, but the published evidence is often hampered by …

Associations between modifiable exposures and disease seen in observational
epidemiology are sometimes confounded and thus misleading, despite our best efforts to …

Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …

Acute myeloid leukemia (AML) is a heterogenous disease with outcomes dependent upon
several factors, including patient age, karyotype, mutational status, and comorbid conditions …

Abstract In the European Organization for Research and Treatment of Cancer Leukemia
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …

Patients under 55 years in the United Kingdom Medical Research Council Acute Myeloid
Leukaemia 10 trial who entered complete remission were tissue typed (n= 1063). Four …

To prospectively assess the applicability of reduced-intensity conditioning hematopoietic
stem cell transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 …

Background: Acute myeloid leukemia (AML) is a clonal disease characterized by the
proliferation and accumulation of myeloid progenitor cells in the bone marrow, which …